Goldenwell Biotech, Inc. (OTC: GWLL)

Goldenwell Biotech, Inc. is an early stage corporation incorporated in the State of Nevada on August 20 2019 and it has established a fiscal year end of December 31. The company focuses on the development and sale of nutraceutical and dietary supplement products. To date the company has limited operations and has generated minimal revenue resulting in recurring losses from operations. As of September 30 2025 the company reported cash of $45,622 inventory of $174,788 and a related party loan of $95,588. The working capital balance was negative $94,823 and the company has stated that substantial doubt exists about its ability to continue as a going concern without additional financing.

Revenue is generated primarily through the sale of its nutraceutical and dietary supplement products. During the three month period ended September 30 2025 the company recorded sales of $0 and during the nine month period ended September 30 2025 it recorded sales of $297. For the nine month period ended September 30 2024 the company recorded sales of $62,500 from its nutraceutical and dietary supplements business. The company has not generated positive cash flow from operations with net cash used in operations of $3,781 for the nine month period ended September 30 2025 and $97,726 for the nine month period ended September 30 2024. Net losses were $7,985 for the three month period ended September 30 2025 and $47,581 for the nine month period ended September 30 2025. To increase sales the company plans to construct manufacturing facilities which includes locating a site installing a workshop and setting up equipment at an estimated cost of approximately $5,000,000 and a timeline of about one year.

Within the nutraceutical and dietary supplements industry Goldenwell Biotech, Inc. operates as an early stage entrant with limited market presence and no established brand recognition. The company faces competition from large established manufacturers and distributors that have broader product lines and greater scale. Goldenwell Biotech, Inc. does not yet possess proprietary formulations patents or large scale production capabilities that would provide a distinct competitive advantage. The company states that no special equipment needs to be engineered or produced and that all needed equipment is presently available from existing manufacturers. Its ability to compete will depend on securing financing to build infrastructure achieve product scale and develop a reliable supply chain.

The company plans to sell its nutraceutical and dietary supplements to individual consumers and retail outlets such as health stores pharmacies and online platforms. No specific customer names have been disclosed in the filing. Consequently the customer base is described broadly as end users who purchase dietary supplements for personal health and wellness. The company intends to develop distribution channels once manufacturing capacity is established and sufficient working capital is available. Until then the company has not generated meaningful sales and remains dependent on future fundraising to reach its target market.